

Bioscience Business


Vision

We will contribute to the resolution of social issues related to health and medical care by developing new products that closely track developments in medical treatment.

Business Overview

Nichirei Biosciences is utilizing the Nichirei Group's ingredient procurement capabilities and technological strength in the biotechnology field to conduct business in the areas of molecular diagnostics, rapid diagnostics, raw materials for biologics manufacturing and functional materials.

We aim to contribute to the development of the medical, health and biological industries by harnessing the technical prowess, procurement capabilities and quality assurance capabilities that we have developed thus far through high-quality products and services.

 Nichirei Biosciences Inc.
<https://www.nichirei.co.jp/bio/english/index.html>

Strengths


We are one of the few developers and manufacturers. Our advanced development capabilities and skilled human resources in this area make us competitive with global companies. We benefit from having:

- Technological strength that allows us to create and provide stable supplies of high-quality products from biologically derived raw materials
- Abundant knowledge and technological experience related to cells and antibodies



Masato Takenaga

Executive Officer, Nichirei Corporation
Representative Director, President,
Nichirei Biosciences Inc.



Companion diagnostics *Histofine ALK iAEP®* Kit
(in vitro diagnostic kit)



Influenza virus rapid diagnostics
Immunofine™ FLU (rapid diagnostic kit)



Functional Materials
ACEROLA EXTRACT WB (NICHIREI)
(Acerola fruit extract)

Medium-term Business Plan (FY2020–2022): WeWill 2021

* Fiscal years (FY) indicate years ended March 31.

Strategies

Using the global innovation center it established in 2019, Nichirei Biosciences is focusing on developing new products to reflect its earlier development investments.

In the field of medical care, we are witnessing the creation of drugs that focus on the immune system to fight cancer and have few side effects, while other new treatment methods, such as regenerative medicine, are also emerging on the scene.

Diagnostic s and medical devices are playing an increasingly important role in selecting which of these treatment methods is most appropriate for a patient.

In response to this trend, Nichirei Biosciences is contributing to cutting-edge medical treatment by manufacturing diagnostics using its technologies and knowledge concerning cells, immunology and antibodies. The diagnostics are then sold together with medical devices.

To further our contributions and increase development speed, we will also redouble our open innovation efforts, conducting joint development with universities, start-up companies and pharmaceutical companies.

Through our functional materials business, we are manufacturing and selling extracts derived from plants and the placenta.

When developing these products, we perform the minimum possible animal experiments, out of consideration for animal welfare. We also take into account customer needs on a societal level, developing and testing organic products.

Overseas, we are implementing integrated management encompassing the development, production and sale of medical devices and diagnostics. For this we are collaborating with Pathcom Systems Corporation, which we acquired in March 2019. We aim to expand our operations globally, using our diagnostics' business in the US as a foothold.

All of Nichirei Biosciences' businesses operate using biological materials that are subject to fluctuations in quality. Despite this, we pride ourselves on our ability to maintain a high level of product quality by ensuring stable production and quality control.

As members of the Nichirei Group, we will produce high-quality products to ensure safety and security and elevate our global presence by increasing the added value of our products with our highly specialized personnel and technology.

Main Measures

- **Japan**
 - Promote the development and commercialization of next-generation diagnostics and instruments
 - Establish stable production technology and increase customer satisfaction by strengthening quality control
 - Create a business model reflecting technological innovations and changing needs
 - Strengthen intellectual property management to effectively deal with business globalization
- **Overseas**
 - Promote business expansion, using US operations as a foothold
- **ESG**
 - Build good relationships with regional communities around Global Innovation Center
 - Improve productivity, while employing and training diverse human resources and implementing work-style reforms

External Environment (three-year outlook)

- Opportunities**
- Structural changes in medical systems and a growing number of patients due to the aging of societies around the world
 - Tight healthcare financing and increased public health awareness
 - Increasing demand for diverse diagnostics and medical devices, due to advances in medical care
- Risks**
- Intensified global competition involving medical companies
 - Growing risk of new infectious diseases due to climate change

Global Innovation Center

Nichirei Biosciences established Global Innovation Center that will function as a new base for production and R&D in Sayama-shi, Saitama Prefecture. Full-scale operations began at the facility in June 2019.

The facility will enable us to expand the expertise and technologies we have accumulated over the years, while responding to diversifying customer needs by encouraging innovation through in-house, domestic and overseas exchanges.



- Features of Global Innovation Center
- Office spaces that encourage frequent close communication and cooperation among users
 - Web-linked conference rooms for global communication
 - Seismic isolation structure to ensures business continuity
 - Use of latest energy-saving technology

- Overview of the Global Innovation Center
- **Name:** Nichirei Biosciences Global Innovation Center
 - **Location:** 1-11-8 Shin-sayama Sayama-shi Saitama prefecture
 - **Chief:** Koichi Obayashi, Director Managing Executive Officer, Nichirei Biosciences Inc.
 - **Building specs:** Four stories, building area of 2,207 m², total floor area of 7,681 m²
 - **Uses:** Life science R&D and production of diagnostics and ingredients used in cosmetics and food